15 U.S. sites make medicines used in PET scans. GE HealthCare has agreed to buy SOFIE Biosciences.
GE HealthCare has agreed to acquire SOFIE Biosciences, gaining U.S. rights to Phase III imaging agent FAPI-74. The deal expands GE HealthCare's footprint in the U.S. radiopharmaceutical market, enhancing access to PET radiopharmaceuticals. SOFIE operates 15 sites and is expected to grow in the low double digits. GE HealthCare anticipates the transaction will be accretive to revenue and earnings.
How this was made
The 30-second read
Why it matters
The acquisition is positioned as a strategic move to capture the growing PET radiotracer market and improve end‑to‑end supply.
Market read
First‑report acquisition news for a large cap; likely to move GEHC stock and affect the radiopharma sector.
What to watch
Regulatory approvals for FAPI-74 and potential competition from other PET tracers.
Background
GE HealthCare is expanding its pharmaceutical diagnostics business by acquiring a network of 15 U.S. CMO sites.
Ticker impact
GE HealthCare announced it will acquire SOFIE Biosciences, adding U.S. rights to the Phase III PET tracer FAPI-74.
likely upside as the market prices in revenue growth and margin expansion from the acquisition.
Large‑cap M&A with strategic fit; management highlighted accretive impact, and investors typically reward such announcements.
Market effects
strengthens the U.S. PET radiopharmaceutical supply chain, potentially boosting related CMO stocks.
U.S. healthcare and diagnostics sector may see modest buying pressure.
reinforces GE HealthCare's global leadership in imaging and could influence global radiopharma competitors.
Counterpoint
Integration risks and execution challenges could delay expected synergies, weighing on the stock.
Key entities
- companyGE HealthCare Technologies Inc.
U.S.-listed healthcare technology and diagnostics firm (ticker GEHC).
- companySOFIE Biosciences
Private radiopharmaceutical manufacturer with 15 U.S. CMO sites.
